Using Oral Valacyclovir to Treat Patients With Refractory IC/BPS

Sponsor
Buddhist Tzu Chi General Hospital
Study ID
NCT05094414
Phase
PHASE1
Status
Unknown

Conditions

  • Overactive Bladder Syndrome
  • Pain, Chronic
  • Quality of Life
  • Urge Incontinence

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Valacyclovir — DRUG
    oral valacyclovir 500 mg twice per day for 4 weeks

Study Details

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a collective term referring to disorders which is characterized by lower urinary tract symptoms, including bladder pain/discomfort, frequent urination without evidence of bacterial infection. The etiology of IC/BPS is still uncertain, and most current treatment for IC/BPS are only symptoms control. Our previous study revealed Epstein-Barr virus (EBV) infection presented in the IC/BPS bladders and involved the pathogenesis. Hence, using anti-viral medication valacyclovir for the patients with IC/BPS might have clinical efficacy.

Key Dates

Start date
Jul 1, 2021
Status verified
Oct 2021
Primary completion
Feb 28, 2022
Completion
Apr 30, 2022

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Global Response Assessment (GRA) [ Time Frame: 1 month ]

Related Studies